Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis

The growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis regulates bone remodelling and metabolism. This Review highlights the pathophysiological and clinical aspects of skeletal fragility associated with perturbations in the GH-IGF1 axis such as GH deficiency, anorexia nervosa, ageing and acromegaly. Growth hormone (GH) and insulin-like growth factor 1 (IGF1) are important regulators of bone remodelling and metabolism and have an essential role in the achievement and maintenance of bone mass throughout life. Evidence from animal models and human diseases shows that both GH deficiency (GHD) and excess are associated with changes in bone remodelling and cause profound alterations in bone microstructure. The consequence is an increased risk of fractures in individuals with GHD or acromegaly, a condition of GH excess. In addition, functional perturbations of the GH-IGF1 axis, encountered in individuals with anorexia nervosa and during ageing, result in skeletal fragility and osteoporosis. The effect of interventions used to treat GHD and acromegaly on the skeleton is variable and dependent on the duration of the disease, the pre-existing skeletal state, coexistent hormone alterations (such as those occurring in hypogonadism) and length of therapy. This variability could also reflect the irreversibility of the skeletal structural defect occurring during alterations of the GH-IGF1 axis. Moreover, the effects of the treatment of GHD and acromegaly on locally produced IGF1 and IGF binding proteins are uncertain and in need of further study. This Review highlights the pathophysiological, clinical and therapeutic aspects of skeletal fragility associated with perturbations in the GH-IGF1 axis.

Automated summary

This review highlights the pathophysiological, clinical and therapeutic aspects of skeletal fragility associated with perturbations in the GH-IGF1 axis, such as GH deficiency, anorexia nervosa, ageing and acromegaly. These perturbations cause changes in bone remodelling, increase the risk of fractures, and can affect the effectiveness of treatment.